RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:494454

Vulvar adenocarcinoma

high confidenceSubtype of disorder

Also known as: Adenocarcinoma of the vulva

Publications

315

74.9th percentile

Trials

4

Interventional, condition-specific

Researchers

1,139

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare vulvar carcinoma characterized by a malignant epithelial neoplasm of glandular origin and/or with glandular characteristics arising in the vulva, including adenocarcinoma of mammary gland type, sweat gland type, and intestinal type, as well as adenocarcinomas of the Bartholin glands and Paget disease of the vulva. Depending on the type of tumor and disease stage, patients may present with a solitary vulvar mass, bleeding, or (in the case of Paget disease) a pruritic, erythematous, eczematous lesion.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

adenocarcinoma of the vulva · adenocarcinoma of vulva · mammalian vulva adenocarcinoma · vulva adenocarcinoma · vulvar adenocarcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    315 matched papers (159 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    4 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

315

315 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

315 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

159 in the last 10 years · high confidence · 74.9th percentile (publications denominator)

Phrase hits: 315 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,139

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Musella A4 papers · 2019

    Department of Obstetrics and Gynecology, "Sapienza" University, Viale del Policlinico 155, 00155 Rome, Italy.

    Papers in Europe PMC
  2. 02
    Cormio G3 papers · 2022

    Department of Gynecology, Gynecologic Oncology Unit, Obstetrics and Neonatology (DIGON), University of Bari, Bari, Italy.

    Papers in Europe PMC
  3. 03
    Karnezis AN3 papers · 2023

    Department of Pathology and Laboratory Medicine, UC Davis, Sacramento, CA, USA.

    Papers in Europe PMC
  4. 04
    Kato T3 papers · 2025

    1 National Cancer Center Hospital, Tokyo, Japan.

    Papers in Europe PMC
  5. 05
    Liu X3 papers · 2024

    Faculty of Medicine, University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia.

    Papers in Europe PMC
  6. 06
    Scambia G3 papers · 2020

    Unità di Ginecologia Oncologica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.

    Papers in Europe PMC
  7. 07
    Tessier-Cloutier B3 papers · 2022

    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

    Papers in Europe PMC
  8. 08
    Yoshida H3 papers · 2025

    1 National Cancer Center Hospital, Tokyo, Japan.

    Papers in Europe PMC
  9. 09
    Arciuolo D2 papers · 2025

    Unità di Gineco-Patologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.

    Papers in Europe PMC
  10. 10
    Argani P2 papers · 2022

    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

4

interventional trials for this specific condition

4 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 3,688 trials are registered for adenocarcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

4 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 86.7th percentile).

high confidence · 86.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

4 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: adenocarcinoma

3,688

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Vulvar adenocarcinoma" OR "Adenocarcinoma of the vulva" OR "Adenocarcinoma of vulva" OR "mammalian vulva adenocarcinoma" OR "vulva adenocarcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Vulvar adenocarcinoma" OR "Adenocarcinoma of the vulva" OR "Adenocarcinoma of vulva" OR "mammalian vulva adenocarcinoma" OR "vulva adenocarcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 4 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"adenocarcinoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T17:32:34.583Z